Trial Profile
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Endometrial cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms DOMEC
- 11 Mar 2022 Results published in the Gynecologic Oncology
- 30 Mar 2021 Planned End Date changed from 1 Jul 2023 to 1 Aug 2021.
- 30 Mar 2021 Planned primary completion date changed from 1 Jul 2023 to 1 Aug 2021.